Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03915028
Other study ID # 2018-A02411-54
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 23, 2019
Est. completion date August 2021

Study information

Verified date March 2019
Source Association Francaise pour la Recherche Thermale
Contact Isabelle LAFFONT
Phone 04 67 33 23 46
Email i-laffont@chu-montpellier.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Multiple Sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, with significant public health consequences. The benefit of spa treatments on the quality of life in this population has not been evaluated. The methods of study in clinical pharmacology can be a scientific methodological model for the evaluation of thermal practices and it is in this perspective that investigators want to lead this project.


Description:

Multiple sclerosis (MS) is a chronic, progressive disease with a high prevalence in France, and its consequences in terms of public health are important. In this disease, the alteration of the quality of life (QoL) is constant and multifactorial : pain, fatigue, decrease in functional capacities, sleep disorders, cognitive disorders, vesico-sphincterian disorders, anomolytic disorders. -rectal and genito-sexual. The benefit of thermal cures on the quality of life in this population has not been evaluated, even if there is some literature in the literature suggesting a benefit of hydrotherapy on equilibrium or on pain.


Recruitment information / eligibility

Status Recruiting
Enrollment 200
Est. completion date August 2021
Est. primary completion date May 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- Patient with primary or progressive secondary-phase MS

- Showing EDSS <7 severity criteria

- Patient with MS for whom an indication of spa treatment has been made,

- Patient agreeing to participate in this study and therefore accepting the constraints related to the design "immediate cure-deferred cure",

- Patient receiving the general social security scheme,

- Patient having given written consent to participate in the study

Exclusion Criteria:

- Patient does not meet the inclusion criteria,

- Patient with relapsing remitting MS

- Patient unfit according to the investigator to complete the rating scales

- Patient with heat intolerance called "Uhthoff effect"

- Patient with a contraindication to the spa treatment: urinary or faecal leakage, wound, thrombophlebitis less than three months old, unstabilized cardio respiratory disease.

- Patient with serious life-threatening condition (ie, cancer)

- Patient under tutorship or curatorship

- Patient participating in another interventional clinical research project

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Spa therapy
The standardized treatment will consist of 4 spa treatments per day for 3 consecutive weeks. Each day, the patient receives at least four treatments, among which: Cure of Drink (in addition to 4 daily cares) Bath in running water: Bath Bath in running water: Pool at 32 ° C Bath with aerobain Immersion shower bath Shower of high pressure under immersion in swimming pool General penetrating shower General jet shower Local jet shower Local mud bath at the feet Single poultice Multiple poultice Compress Mobilization pool Massages under water

Locations

Country Name City State
France Département de Médecine Physique et de Réadaptation, Hopital LAPEYRONIE Montpellier

Sponsors (1)

Lead Sponsor Collaborator
Association Francaise pour la Recherche Thermale

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Benefit of spa treatment on quality of life assessed by the scale SEP-59 Difference of the score of quality of live assessed by the scale SEP-59 between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. SEP-59 is built on the basis of a generic scale, the SF-36. The analysis of SEP-59 is done by computer processing in order to calculate the score of the various axes (pain, physical activity, general wellbeing ...) which are independent (there is no overall score). within 15 weeks after inclusion
Secondary Benefit of a spa treatment based on average number of steps per day for one week assessed by actimeter Difference of the average number of steps per day for one week between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. 9 weeks after inclusion
Secondary Benefit of a thermal cure based on treatment consumption of hospital and ambulatory care Difference of the number of treatment consumption of hospital and ambulatory care between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately 15 to 17 weeks after inclusion
Secondary Benefit of a thermal cure based on depression and anxiety assessed by the scale Hospital Anxiety and depression scale Difference of the level of pain assessed by the scale Hospital Anxiety and depression between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately.HADS is a self-administered scale of 14 items, divided into 2 subscales of 7 items (Anxiety or HADS-A, Depression or HADS-D). It contains no somatic item that can be confused with symptomatic manifestations of a disease.
Each item is scored on a scale of 0 to 3. A score is generated for each of the two sub-scales and for the entire HADS (HADS-T).
Limit scores distinguish between: non-cases or asymptomatic cases (score = 7); probable or borderline cases (score 8-10); clearly or clinically symptomatic cases (score = 11).
15 to 17 weeks after inclusion
Secondary Benefit of a thermal cure based on tiredness assesed by the fatigue impact scale Difference of the level of pain assessed by the fatigue impact scale between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately. It is a self-assessment tool in which the patient is asked to note the extent to which fatigue has caused them problems in certain situations. (0 = no problem, 4 = extreme problems). A maximum score of 160 is obtained for the 40 items. 15 to 17 weeks after inclusion
Secondary Benefit of a thermal cure regarding pain assessed by the scale DN 4 Difference of the level of pain assessed by the DN4 scale between the patient will receive the immediat spa therapy and the second group which won't receive the spa therapy immediately 15 to 17 weeks after inclusion
See also
  Status Clinical Trial Phase
Completed NCT05528666 - Risk Perception in Multiple Sclerosis
Completed NCT03608527 - Adaptive Plasticity Following Rehabilitation in Multiple Sclerosis N/A
Recruiting NCT05532943 - Evaluate the Safety and Efficacy of Allogeneic Umbilical Cord Mesenchymal Stem Cells in Patients With Multiple Sclerosis Phase 1/Phase 2
Completed NCT02486640 - Evaluation of Potential Predictors of Adherence by Investigating a Representative Cohort of Multiple Sclerosis (MS) Patients in Germany Treated With Betaferon
Completed NCT01324232 - Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Phase 2
Completed NCT04546698 - 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis
Active, not recruiting NCT04380220 - Coagulation/Complement Activation and Cerebral Hypoperfusion in Relapsing-remitting Multiple Sclerosis
Completed NCT02835677 - Integrating Caregiver Support Into MS Care N/A
Completed NCT03686826 - Feasibility and Reliability of Multimodal Evoked Potentials
Recruiting NCT05964829 - Impact of the Cionic Neural Sleeve on Mobility in Multiple Sclerosis N/A
Withdrawn NCT06021561 - Orofacial Pain in Multiple Sclerosis
Completed NCT03653585 - Cortical Lesions in Patients With Multiple Sclerosis
Recruiting NCT04798651 - Pathogenicity of B and CD4 T Cell Subsets in Multiple Sclerosis N/A
Active, not recruiting NCT05054140 - Study to Evaluate Efficacy, Safety, and Tolerability of IMU-838 in Patients With Progressive Multiple Sclerosis Phase 2
Completed NCT05447143 - Effect of Home Exercise Program on Various Parameters in Patients With Multiple Sclerosis N/A
Recruiting NCT06195644 - Effect of Galvanic Vestibular Stimulation on Cortical Excitability and Hand Dexterity in Multiple Sclerosis Patients Phase 1
Completed NCT04147052 - iSLEEPms: An Internet-Delivered Intervention for Sleep Disturbance in Multiple Sclerosis N/A
Completed NCT03591809 - Combined Exercise Training in Patients With Multiple Sclerosis N/A
Completed NCT03594357 - Cognitive Functions in Patients With Multiple Sclerosis
Completed NCT02845635 - MS Mosaic: A Longitudinal Research Study on Multiple Sclerosis